ACHE and chronic obstructive pulmonary disease: Edrophonium, an FDA-approved acetylcholinesterase inhibitor for myasthenia gravis diagnosis, cardiac arrhythmia management, and neuromuscular blocking agent toxicity reversal, induces mild cholinergic effects, including bradycardia and bronchoconstriction (Pakala et al., 2023).